There’s No Hepatitis C Vaccine, But You Can Still Prevent Infection
“MONDAY, June 12, 2023 (HealthDay News) — Hepatitis C can ruin your liver, and there’s no vaccine to prevent it, but you can take steps to lower your chances of infection.”
Op-ed | Sharpening your needles in a fight against Hepatitis C
“Hey Bronxites! Let’s play a game of two truths and a lie regarding Hepatitis C.
- Out of the 10 neighborhoods with the highest rates of people newly reported with chronic Hepatitis C in New York City, five were located in the Bronx.
- The main mode of transmission for Hepatitis C is sexual transmission.
- There is no Hepatitis C vaccine.
I played this little game with my small group of friends who are pre-med, pre-dental and other pre-health majors, and 83% of them chose three as the lie. And if you did too, unfortunately and unexpectedly, that is the common wrong answer.”
Hepatitis C Virus Deaths are Largely Underreported
“A new analysis of mortality and morbidity highlights a growing issue with counting hepatitis C virus-related deaths as they are largely underreported.”
IDSA, AASLD Hepatitis C Guidelines Offer Strategies for Incomplete Adherence
“The Infectious Disease Society of America and the American Association for the Study of Liver Diseases have released updated guidance on testing for, managing, and treating hepatitis C virus (HCV) infection. The guidelines offer new strategies for physicians managing patients who are not completely adherent to direct-acting antiviral (DAA) therapy, and also reiterate the importance of universal screening in the fight to stop transmission of the virus.”
Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination
“BOSTON, June 15, 2023 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the dosing of the first patient in the Phase 2 bemnifosbuvir and ruzasvir combination study for the treatment of Hepatitis C Virus (HCV) infection.”
HIV-Positive Women With Health Insurance Are More Likely to Get Hepatitis C Treatment
“Women living with HIV who have health insurance are much more likely to start direct-acting antiviral therapy for hepatitis C than those who do not have insurance, but those covered by Medicaid are less likely to initiate treatment than those with private insurance, according to study findings published in Clinical Infectious Diseases.”
Hepatitis C virus transmission between eight high-income countries among men who have sex with men: a whole-genome analysis
“Microelimination of the hepatitis C virus (HCV) among men who have sex with men (MSM) could be complicated by continuous external introductions and the emergence of phylogenetic clusters harbouring clinically significant resistance-associated substitutions (RAS). To investigate international clustering and the prevalence and transmission of RAS, we aimed to analyse whole-genome HCV sequences from MSM with a recently acquired infection who participated in a large, international HCV treatment trial.”
Correlation of Model for End Stage Liver Disease (MELD), MELD-Sodium (MELD-Na), and Child-Turcotte-Pugh (CTP) Score With Frailty in Patients With Hepatitis C Virus (HCV) Related Cirrhosis
“Introduction: The model for end stage liver disease (MELD), model for end stage liver disease-sodium (MELD Na), and Child-Turcotte-Pugh (CTP) score are independent predictors of mortality in cirrhotic patients. Approximately 43% of cirrhotic patients with advanced disease are frail and can have detrimental effects on the disease prognosis and survival including delisting from the transplant list and increased risk of post-transplant complications. Therefore, our aim was to determine the correlation of MELD, MELD-Na, and CTP score with frailty in patients with hepatitis C virus (HCV) related cirrhosis.”
Video:
Updates on HCV Screening, Access to Treatment, and Prevention : Episode 1
HCV: A Population Health Perspective
“Parvez Mantry, MD, discusses the burden of HCV and challenges to diagnosis and therapy. He also explores general awareness regarding HCV and opportunities for screening.”
